Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (July 2018)
30 slides from Inspiremd's investor presentation, Jul 9, 2018
Slide 1: Investor Presentation
inspireMD Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspireMD This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," will,” "plans," "expects," “anticipates,” "projects," "predicts," “estimates,” "aims," "believes," "hopes," "potential" or similar words. Forwa
Slide 3: About InspireMD
About InspireMD inspireMD InspireMD is a commercial-stage medical device company developing and marketing innovative embolic prevention systems (EPS) that can prevent harmful consequences associated with conventional medical device procedures, with a primary focus on preventing stroke in patients wi
Slide 4: Stroke: the second biggest cause of death globally
Stroke: the second biggest cause of death globally inspireMD * There are 15 million new strokes a year 4 + $34BB in healthcare costs in the U.S. is associated with stroke management? * In 2016, 5.7 million deaths, were caused by stroke! 9 * 7.3 milli I ffected by stroke? + 5 million people/year are
Slide 5: Addressable device market in stroke prevention
Addressable device market in stroke prevention inspireMD “CAD is aeae “The +2.2MM underdiagnosed fone addressable patients are and needs to be . device market diagnosed with treated to Robes is calculated to CAD __ reduce the opportunity Gee! impact of stroke billion * 2017: ~600,000 patients with h
Slide 6: Stroke prevention in CAD: Surgery vs. Carotid Artery Stenting
Stroke prevention in CAD: inspireMD Surgery vs. Carotid Artery Stenting P Based on CREST trial data, in which only conventional carotid stents were used Carotid Endarterectomy Filter Protected Stenting (e=,)) ((@XS)) + Low stroke risk’, but... + Patient friendly, long-term _— . ility! + Invasive: ri
Slide 7: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization, e
Slide 8: Consequences Range from Neurological Deficit to Stroke
Co Ww it to Stroke n Defi Ss Cc equences Range from Neurological SR Pre-Procedure Pre-intervention showing 90% occlusion of the carotid artery and an MRI showing an old white matter infarction (obstruction). Cano etal. Rev Bras Cardiol Invasiva 2013; 2 Post-Procedure Post-intervention showing succes
Slide 9: CGuard EPS has been shown to prevent embolic debris passing into the carotid artery
CGuard™ EPS has been shown to prevent embolic debris passing into the carotid artery inspire Conventional Carotid Stent Carotid plaque can protrude through the mesh Plaque protrusion may lead to early and late distal embolization Arterial uf Wall Pa Debris CGuard™ EPS The MicroNet™ permanently cover
Slide 10: Conventional Carotid Stents vs CGuard EPS
Conventional Carotid Stents 4 CGuard™ EPS 2 The MicroNet™ permanently covers plaque and No plaque coverage - leading to plaque protrusions j prevents “debris” from passing through the mesh. or prolapse passing into the vessel lumen Conventional Stent ; i MicroNet mesh preventing prolapse ‘Yoshimura,
Slide 11: The potential paradigm shift with CGuard
The potential paradigm shift with CGuard™ inspireMD Carotid procedures tomorrow Carotid procedures today are could be mostly minimally invasive with CGuard™ primarily surgical mCEA @CAS BCAS 80% of Market MicroNet™ covered stents could become the Gold Standard = 20% of Market 100% of addressable mar
Slide 12: CGuard: market potential in stroke prevention
CGuard™ : market potential in stroke prevention inspireMD In 2016... +~600,000 (30%) -2.2 million people were diagnosed with a high grade carotid stenosis (HGS) plus the undiagnosed patients estimated at more than 10 million high grade carotid Stenosis Proportion of diagnosed HGCS patients who recei
Slide 13: fia eh
3 fia eh Postepy Kardiol Interwencyine} CREST https Intemal data www nejm.org/doiffull 10.10: e Is accumu proceaura 17; 13(2): 95~-106 |EJMoa0912321 mplications YHCAUOTIS
Slide 14: Positive CGuard Clinical Experience
Positive CGuard™ Clinical Experience inspireMD CARENET Clinical Trial (2014) + 30 Patient Safety and Efficacy clinical trial + Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%*) + 50% fewer new ischemic lesions with lesion volume being 10x times smaller compar
Slide 15: Additional Independent Clinical Data
Additional Independent Clinical inspireMD Independent study conducted in 30 patients with internal carotid artery disease meee Clinical Results and Mechanical Propertie: ‘ofthe Carotid CGUARD Double-Layered Embolic Prevention Stent Clinical results (2016) * 100% success in implanting the CGuard™ EPS
Slide 16: Additional Independent Clinical Data
Additional Independent Clinical Data inspirelID SPECIAL ARTICLES The Iron-Guard Registry Towwionsesinamsseree Physician initiated oo ; ; S si Physician-initiated prospective Italian Registry 12 large Italian medical centers of carotid stenting with the C-Guard mesh-stent: 200 p atients the IRON-Guar
Slide 17: CGuard EPS vs conventional stents and surgery
CGuard™ EPS vs conventional stents and surgery inspireMD * CGuard™ shows strong benefits compared to both conventional carotid stents and surgery + CGuard™ is a widely researched next generation carotid device stent (7 completed clinical trials and 4 ongoing trials) « Long term sustained and consist
Slide 18: A leading vascular surgeon's view
, ‘ ZN A leading vascular surgeon’s view InspirelMD (6As a vascular surgeon | am very experienced with CEA. From my perspective the near future will show a shift towards carotid stenting because of mesh covered stents. The CGuard™, in comparison to other [carotid] stents, even in comparison to other
Slide 19: Sales Performance
ae Sales Performance InspirelViD Following the change in sales and distribution strategy in early 2017... * 132% increase in CGuard™ EPS sales InspireMD Q1 Sales (USD) for Q1 2018 compared to Q1 2017 1,200,000 1,000,000 $1,000,000 * 77% increase in company revenues for Q1 200,000 2018 compared to Q1
Slide 20: CGuard EPS - accelerating sales growth
CGuard™ EPS - accelerating sales growth Growth trends have been consistent for 2017/2018 Quarter to quarter Q1 sales have more than doubled 900,000 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 O CGuard™ sales revenues (USD) 358,000 Q1 2017 430,000..." 2.2017 526,000.- 3.2017 _sng.
Slide 21: Accelerating CGuard EPS sales growth: Germany
Accelerating CGuard™ EPS sales growth: Germany InspirelViD * German sales are on a positive trajectory following the change in distributors last year with full implementation occurring mid-way through Q3 2017 * CGuard™ Q1 sales in Germany for 2018 alone are 64% of sales in Germany for the whole of 2
Slide 22: Accelerating CGuard EPS sales growth: Italy
5 Ne Accelerating CGuard™ EPS sales growth: Italy InspirelViD * CGuard™ sales in Italy have been strong over the last three years with continuing momentum * Q1 comparisons between 2017 and 2018 show an 85% increase Italy CGuard sales in USD italy Q1 CGuard sales in USD {600000 556,204 200000 186,324
Slide 23: Implementing our strategy: Overview
Implementing our strategy: Overview inspirelID InspireMD is seeking to become the leading stroke prevention company, focused on reducing the global burden of stroke - Transition Vascular Surgeons to CGuard™ * Advisory boards, surgeon specific clinical registries, centres of excellence 1 * Publish, p
Slide 24: CGuard Product Development
CGuard™ Product Development* inspireMD + USFDA + Pre-IDE FDA submission for CGuard™ February 2017 =D + Formal FDA meeting held April 2017 r * 6-9 months of pre-clinical work required to file IDE application to begin a US clinical trial + Next generation CGuard™ - 5 French CGuard™ + Minimally invasiv
Slide 25: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD * Proprietary platform technology supported by a robust intellectual property portfolio * Continue to strengthen and broaden patent protection globally to enable future pipeline products PATENT RIGHTS ISSUED ALLOWED PENDING Rest of World 33 1 15 25
Slide 26: Leadership
Leadership Significant track records of success Dr. James Barry President and CEO inspirelID Boston: GED Craig Shore CFO @ @ [or James ary | [craigshore Director obese = OieartFiow: ,.Cordis. @axvaro es ANd Karec Sec cong Special Advisor to the Board Ge ea! 7i]
Slide 27: Recent/Upcoming Anticipated Milestones
Recent/Upcoming Anticipated Milestones inspireMD Continued clinical trial/registry results CGuard Partnership in approval and Major Asia CGuard U.S. launch in Mexico: H1 2018 Pacific Market IDE submi H1 2019 H1 20197 CGuard Establish approval in Vascular Brazil and 5 French Surgery Austrailia H2 Pee
Slide 28: Summary
Summary inspireMD + Focused on the deadly and catastrophic problem of stroke that is estimated to cost the healthcare system more than $34BB annually in the US alone + The current addressable market for CGuard™ EPS is estimated to be $1BB with the potential to further expand into the 1.6MM patient p
Slide 29: Financial Snapshot
Financial Snapshot inspireMD NYSE AMER: NSPR Stock e (7/6/2018): $0.25 Average 3 Month Volume (7/6/2018): 886 K Shares Outstanding (7/6/2018): 21.7M Shares Outstanding Including full conversion of preferred shares and prefunded warrants (7/6/20188): aan Market Capitalization including full conversio
Slide 30: InspireMD
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com